GlassScriptPhysician profile
Sunil K Saraf
NPI 1376506295
$8,809.49
in general payments reported to CMS, 2019-2025
36 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $845 · 2021: $1,117 · 2022: $1,533 · 2023: $1,503 · 2024: $1,412 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,307 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,307.33 |
| Education | $221.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,305.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,057.50 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $958.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $763.90 | 2019-2025 | Dupixent |
| Pfizer INC. | $623.38 | 2019-2025 | |
| Csl Behring | $536.14 | 2019-2025 | Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $527.44 | 2020-2025 | Takhzyro, Cuvitru |
| Novartis Pharmaceuticals Corporation | $415.49 | 2019-2025 | |
| Grifols USA, LLC | $409.90 | 2019-2025 | Xembify |
| Amgen INC. | $317.69 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $304.22 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.11 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $179.65 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $170.73 | 2025 | Neffy |
| Kaleo, INC. | $136.25 | 2019-2024 | Auvi-Q |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $125.97 | 2025 | |
| Shire North American Group INC | $125.83 | 2019 | |
| Hospira, INC. | $69.25 | 2024-2025 | |
| Ionis Pharmaceuticals, INC. | $69.15 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $63.04 | 2021-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $52.09 | 2021-2023 | Orladeyo |
| Blueprint Medicines Corporation | $45.86 | 2024 | Ayvakit |
| Verona Pharma, INC. | $40.13 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $39.86 | 2019 | |
| Octapharma USA, INC. | $38.82 | 2020 | |
| Uswm, LLC | $34.00 | 2021 | |
| Gc Biopharma USA, INC. | $25.51 | 2025 | Alyglo |
| Sanofi-Aventis U.S. LLC | $25.00 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $23.09 | 2020 | |
| Azurity Pharmaceuticals, INC. | $22.65 | 2025 | Horizant |
| Leo Pharma INC. | $21.38 | 2022 | |
| Aimmune Therapeutics, INC. | $19.62 | 2021 | |
| Merck Sharp & Dohme LLC | $18.94 | 2023 | |
| Incyte Corporation | $18.83 | 2021 | |
| Genentech USA, INC. | $18.50 | 2019 | |
| Abbvie INC. | $13.00 | 2023 | Rinvoq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Saraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.